Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
"Weight loss medications are not one size fits all and patients should always discuss options with a trusted medical professional," one expert told Newsweek.
Novo Nordisk, the maker of Ozempic and Wegovy, said its experimental weight-loss pill lowered participants' body weight by up ...
GLP-1 supplements are advertised as a cheaper alternative to weight loss with Ozempic or Wegovy. Doctors explain if they help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback